Skip to main content
OpenTrials

Clinical trial condition

Ovarian Diseases

Explore clinical trials studying Ovarian Diseases. Study availability and eligibility vary by location and protocol.

3,406 public trials 661 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Diseases trial results

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

NCT01618136

Conditions
Adnexal Diseases, Advanced Melanoma, B-cell Malignancy, Low-grade, +37 more
Locations
  • King's College London Guy's Hospital Campus London, United Kingdom
  • Newcastle Upon Tyne NHS Foundation Trust Newcastle Upon Tyne and Wear, United Kingdom
View Trial Details
Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

NCT01891344

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +26 more
Locations
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Saint Jude Heritage Medical Center Fullerton, California, United States
  • University of California Los Angeles Los Angeles, California, United States
View all 75 locations
View Trial Details
Completed

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

NCT02855944

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +26 more
Locations
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • Augusta University Augusta, Georgia, United States
  • Hospital Haroldo Juacaba Instituto do Cancer do Ceara Fortaleza, Ceará, Brazil
  • Instituto de Oncologia do Parana (IOP) Curitiba, Paraná, Brazil
View all 77 locations
View Trial Details
Completed

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

NCT01482715

Conditions
Adnexal Diseases, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA, Disease Attributes, +22 more
Locations
  • UCSF San Francisco, California, United States
  • Sarah Cannon Research Institute Sarasota, Florida, United States
  • Dana-Farber Cancer Institute (Part 3 only) Boston, Massachusetts, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
View all 16 locations
View Trial Details
Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

NCT01968213

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Saint Jude Heritage Medical Center Fullerton, California, United States
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 96 locations
View Trial Details
Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

NCT01847274

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 112 locations
View Trial Details

Related conditions